RGX-314, Regenxbio’s gene therapy using NAV vectors for AAV-mediated antibody delivery, has shown positive phase 1/2a results in patients with wet age-related macular degeneration, continuing to be well tolerated across five dose cohorts, according to a press release.
Forty-two subjects have been treated in the trial, and dose-independent increases in RGX-314 protein expression levels, measured from aqueous samples by electrochemiluminescence immunoassay, have been observed at all dose levels after 1 month of treatment, the release said.
“We are encouraged by the continued positive
Uncategorized